Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

LETTER
[Download PDF
 
Year : 2009  |  Volume : 55  |  Issue : 3  |  Page : 231  

Treatment options for ophthalmoplegic migraine

LIG Granado, G Guillen 
 Department of Pediatrics, Hospital 12 de Octubre, Madrid, Espaņa

Correspondence Address:
LIG Granado
Department of Pediatrics, Hospital 12 de Octubre, Madrid, Espaņa




How to cite this article:
Granado L, Guillen G. Treatment options for ophthalmoplegic migraine.J Postgrad Med 2009;55:231-231


How to cite this URL:
Granado L, Guillen G. Treatment options for ophthalmoplegic migraine. J Postgrad Med [serial online] 2009 [cited 2022 May 26 ];55:231-231
Available from: https://www.jpgmonline.com/text.asp?2009/55/3/231/57389


Full Text

Sir,

The article by Borade et al.[1] provides an excellent description of the clinical picture shown, but regarding short-term and long-term management I would like to present two therapeutic options that were missed in their article, especially when prolonged ophthalmoplegia occurs.

We have to emphasize that ophthalmoplegic migraine is a diagnosis of exclusion, and noninvasive imaging tests such as magnetic resonance angiography (MRA) or magnetic resonance imaging (MRI) should be performed in all cases, to exclude the presence of one aneurysm. Usually ophthalmoplegia is a transient phenomenon. However, it can become permanent, especially after repeated attacks. In this case there are some concerns that longstanding lack of binocularity impedes the recovery of the alignment. For this reason, we can consider botulinum toxin A or surgical realignment (squint surgery) for short- or long-term management, respectively. The injection of botulinum toxin is safe (even for infants) [2] and painless, with appropriate topical analgesia, driven optionally with electromyography (we have been using botulinum toxin for the last four years without moderate or severe adverse effects, so - from our point of view - electromyography would be optional). As it is known, paralysis usually peaks two weeks after the injection. Because of the molecular turnover within the neuromuscular junction and neuronal sprouting, neuronal activity begins to return at three months, with restoration of complete function at approximately six months, so it can provide a longlasting, beneficial effect. It is not only safe and painless, even pain relief could be obtained with this strategy, as it has been proven previously. [3],[4],[5]

Botulinum toxin has previously been shown to produce longlasting recovery of binocular function in some patients with longstanding deviation. [6]

Even though large cohorts of patients are difficult to obtain in such infrequent diseases, we believe that worldwide observational studies could be helpful when deciding if a longlasting therapeutic strategy is needed (and which one) in these patients.

References

1Borade A, Prabhu AS, Kumar S, Prasad V, Rajam L. Magnetic resonance imaging findings in ophthalmoplegic migraine. J Postgrad Med 2009;55:137-8.
2Pascual-Pascual SI, Pascual-Castroviejo I. Safety of botulinum toxin type A in children younger than 2 years. Eur J Paediatr Neurol Nov 2008. doi:10.1016/j.ejpn.2008.10.006 PMID: 1903661
3de Sèze MP, de Sèze M, Dehail P, Joseph PA, Lavignolle B, Barat M, et al. Botulinum toxin A and musculoskeletal pain. Ann Readapt Med Phys 2003;46:329-32.
4Gajraj NM. Botulinum toxin a injection of the obturator internus muscle for chronic perineal pain. J Pain 2005;6:333-7.
5Colhado OC, Boeing M, Ortega LB. Botulinum toxin in pain treatment. Rev Bras Anestesiol 2009;59:366-81.
6Manzouri B, Sainani A, Plant G, Lee J, Sloper J. The aetiology and management of long-lasting sixth nerve palsy in ophthalmoplegic migraine. Cephalalgia 2007;27:275-8.

 
Thursday, May 26, 2022
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer